Chongson

Chong Kun Dang (CKD) is a leading South Korean pharmaceutical company engaged in the research, development, and commercialization of a broad range of healthcare products. The company maintains a robust pipeline focusing on oncology, neurology, and metabolic diseases, with a particular emphasis on innovative small molecules and biologics. CKD is well-known for its expertise in fermentation technology and has successfully developed several proprietary drugs, including the HDAC6 inhibitor CKD-510 and the c-Met targeting antibody CKD-702. Beyond its R&D efforts, the company operates a significant commercial business in Korea, marketing both in-house developed products and licensed-in therapeutics from global partners.